Tolinapant
- Generic Name
- Tolinapant
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C30H42FN5O3
- CAS Number
- 1799328-86-1
- Unique Ingredient Identifier
- 2LHZ9ZC3YO
- Background
ASTX660 is under investigation in clinical trial NCT02503423 (Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas).
- Associated Conditions
- -
- Associated Therapies
- -
Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer
Phase 1
Recruiting
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Invasive Breast CarcinomaLocally Advanced HER2-Negative Breast CarcinomaLocally Advanced Hormone Receptor-Positive Breast CarcinomaLocally Advanced Triple-Negative Breast CarcinomaMetastatic HER2-Negative Breast CarcinomaMetastatic Hormone Receptor-Positive Breast CarcinomaMetastatic Triple-Negative Breast CarcinomaUnresectable HER2-Negative Breast Carcinoma
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT06590558
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center LAO, Columbus, Ohio, United States
Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer
Phase 1
Not yet recruiting
- Conditions
- Recurrent Fallopian Tube High Grade Serous AdenocarcinomaRecurrent High Grade Endometrioid AdenocarcinomaRecurrent Ovarian Seromucinous CarcinomaRecurrent Ovarian Undifferentiated CarcinomaRecurrent Platinum-Resistant Ovarian CarcinomaPlatinum-Refractory Fallopian Tube CarcinomaPlatinum-Refractory Primary Peritoneal CarcinomaRecurrent Fallopian Tube CarcinosarcomaPlatinum-Refractory Ovarian CarcinomaRecurrent Fallopian Tube Undifferentiated Carcinoma
- Interventions
- First Posted Date
- 2024-05-01
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 127
- Registration Number
- NCT06393751
A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-06-03
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Taiho Oncology, Inc.
- Target Recruit Count
- 132
- Registration Number
- NCT05403450
- Locations
- 🇺🇸
Rochester Skin Lymphoma Medical Group, PLLC Site #147, Fairport, New York, United States
🇺🇸University of Pennsylvania Site# 160, Philadelphia, Pennsylvania, United States
🇦🇺Monash Medical Center, Melbourne, Victoria, Australia
Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer
Early Phase 1
Recruiting
- Conditions
- Locally Advanced Laryngeal Squamous Cell CarcinomaHead and Neck Carcinoma of Unknown PrimaryLocally Advanced Head and Neck Squamous Cell CarcinomaLocally Advanced Oropharyngeal Squamous Cell CarcinomaLocally Advanced Hypopharyngeal Squamous Cell CarcinomaLocally Advanced Nasopharyngeal Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2022-02-18
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- Emory University
- Target Recruit Count
- 10
- Registration Number
- NCT05245682
- Locations
- 🇺🇸
Emory University/Winship Cancer Institute, Atlanta, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath